Welcome to our dedicated page for A SPAC III Acqsn SEC filings (Ticker: ASPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on A SPAC III Acqsn's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into A SPAC III Acqsn's regulatory disclosures and financial reporting.
A SPAC III Acquisition Corp. filed its 10-Q, reporting Q3 results and key developments. The company recorded net income of $480,352, driven by interest income of $654,307 on trust investments, offset by general and administrative expenses of $173,955. The trust account held $62,268,671 as of September 30, 2025.
After quarter-end, shareholders redeemed 5,717,419 Class A shares for $59,502,057, leaving about $2.9 million in the trust. Following these redemptions, the Sponsor held approximately 76.4% of 2,337,581 outstanding ordinary shares. The company’s charter extension gives it until November 12, 2026 to complete a merger.
The company signed a merger agreement with Bioserica for total consideration of $217,860,000 in newly issued PubCo shares, subject to customary conditions. Management disclosed substantial doubt about its ability to continue as a going concern if no business combination is completed within the permitted period.
A SPAC III Acquisition Corp. (ASPC) amended its charter to extend the deadline to complete a business combination by 12 months, moving from November 12, 2025 to November 12, 2026, effective October 27, 2025.
Shareholders approved the charter amendment at an extraordinary general meeting on October 27, 2025. Votes cast were 4,178,733 FOR and 2,934,951 AGAINST. As of the October 6, 2025 record date, 8,055,000 ordinary shares were outstanding, and 7,113,684 shares were voted, representing 88.31% of outstanding shares.
An aggregate of 5,717,419 ordinary shares were tendered for redemption in connection with the meeting. Separately, on October 25, 2025, the Sponsor agreed to transfer 100,000 Class B ordinary shares after the consummation of an initial business combination to an unaffiliated third party in exchange for that party voting 621,084 Class A ordinary shares in favor of the amendment.
ASPC seeks shareholder approval to amend its charter to extend the deadline to complete an initial business combination from
The preliminary proxy describes a proposed Charter Amendment to extend ASPC's combination deadline from November 12, 2025 to November 12, 2026 and related shareholder votes. It discloses a May 23, 2025 Merger Agreement to combine with Bioserica via a series of reincorporation and acquisition mergers, which the board unanimously approved and will be submitted to shareholders for separate approval. Public shareholders may redeem for a cash amount equal to the trust account balance (less up to $100,000 for dissolution expenses) divided by outstanding public shares; if the company winds up, rights to receive post-combination ordinary shares will expire worthless. The proxy notes the Sponsor does not currently intend to fund an extension, officers and insiders may not be reimbursed for excess out-of-pocket expenses if no combination occurs, founder/private placement shares remain locked until a business combination, and national security (CFIUS) and other regulatory risks may limit target availability.
FAQ
What is the current stock price of A SPAC III Acqsn (ASPC)?
What is the market cap of A SPAC III Acqsn (ASPC)?
